Abstract
To assess the long-term cost-effectiveness of the insulin degludec/liraglutide combination (IDegLira) versus liraglutide for patients with type 2 diabetes mellitus (T2DM) uncontrolled on oral antidiabetic drugs (OAD) in China.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
